Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956369 | 0.94 | TGFBR1 (0.64) | TGFBR1KDRMAPK14ATREIF4E | |
| SCHEMBL5956553 | 0.90 | TGFBR1 (0.61) | TGFBR1KDRMAPK14ATREIF4E | |
| SCHEMBL5956861 | 0.83 | HPGD (0.51) | TGFBR1KDRMAPK14ATR | |
| SCHEMBL5907453 | 0.81 | TGFBR1 (0.69) | TGFBR1KDRMAPK14ATRMAPKAPK2 | |
| SCHEMBL408704 | 0.80 | TGFBR1 (0.69) | TGFBR1KDRMAPK14ATRMAPKAPK2 | |
| SCHEMBL5907455 | 0.80 | TGFBR1 (0.67) | TGFBR1KDRMAPK14ATRMAPKAPK2 | |
| SCHEMBL6222961 | 0.79 | TGFBR1 (1.00) | TGFBR1KDRMAPK14ATRMAPKAPK2 | |
| SCHEMBL6264300 | 0.79 | TGFBR1 (0.78) | TGFBR1KDRMAPK14ATRMAPKAPK2 | |
| SCHEMBL5956473 | 0.79 | TGFBR1 (0.48) | TGFBR1KDRMAPK14PIK3C3 | |
| SCHEMBL5787523 | 0.77 | TGFBR1 (0.69) | TGFBR1KDRMAPK14ATRGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885KDR 227/4885MAPK14 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.